SCHEDULE: ImmunityBio Ownership Update: Soon-Shiong's Stake at 68.9%
Beneficial Ownership Update (Schedule 13D Amendment)
An amendment to Schedule 13D details the beneficial ownership of ImmunityBio, Inc. common stock by Patrick Soon-Shiong and affiliated entities, with Dr. Soon-Shiong's aggregate stake reaching 68.9%.
Summary
- The filing is an Amendment No. 11 to Schedule 13D for ImmunityBio, Inc. (IBRX), detailing beneficial ownership of its Common Stock.
- As of October 30, 2025, ImmunityBio had 984,965,179 shares of Common Stock issued and outstanding.
- Cambridge Equities, LP beneficially owns 261,705,814 shares, representing 26.6% of the class.
- MP 13 Ventures, LLC is deemed to beneficially own the same 261,705,814 shares, also 26.6%.
- NantWorks, LLC beneficially owns 98,535,253 shares, representing 10.0% of the class, including shares held by its majority-owned subsidiaries NantBio, Inc., NantMobile, LLC, and NantCancerStemCell, LLC.
- NantMobile, LLC's beneficial ownership percentage ceased to be more than five percent of the Issuer's Common Stock as of October 30, 2025, now holding 47,557,934 shares (4.8%).
- Nant Capital, LLC beneficially owns 339,464,529 shares, representing 31.5% of the class, which includes 246,412,277 shares held directly and 93,053,252 shares acquirable within 60 days via conversion of a promissory note.
- California Capital Equity, LLC beneficially owns 106,511,412 shares, representing 10.8% of the class, including shares held directly and those beneficially owned by its wholly-owned subsidiary NantWorks, LLC and its subsidiaries.
- Dr. Patrick Soon-Shiong, the ultimate beneficial owner, holds an aggregate of 743,971,200 shares, representing 68.9% of the class, including direct holdings, exercisable stock options, and shares beneficially owned by various affiliated entities and the Chan Soon-Shiong Family Foundation.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, providing no explicit positive or negative operational or financial news. It primarily updates the market on the ownership structure.
Future Outlook
Nant Capital, LLC has the right to acquire 93,053,252 shares of Common Stock within 60 days of October 30, 2025, through the conversion of a promissory note. Dr. Patrick Soon-Shiong has the right to acquire 1,123,929 shares of Common Stock within 60 days of October 30, 2025, through the exercise of stock options.
Industry Context
This filing is a routine disclosure of beneficial ownership and does not provide information related to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Agreement Disclosure | Disclosure of a Nominating Agreement dated June 18, 2015, between ImmunityBio, Inc. and Cambridge Equities, LP. | 06/18/2015 | This agreement likely outlines rights related to board nominations, influencing corporate governance and board composition. |
| Agreement Disclosure | Disclosure of a Registration Rights Agreement dated December 23, 2014, between ImmunityBio, Inc. and Cambridge Equities, LP. | 12/23/2014 | This agreement grants Cambridge Equities, LP certain rights to have its shares registered for public sale, impacting liquidity and potential future share distributions. |
Related Party Transactions
- The filing details significant beneficial ownership by Dr. Patrick Soon-Shiong and various entities he controls or is affiliated with, including Cambridge Equities, LP, MP 13 Ventures, LLC, NantWorks, LLC, NantMobile, LLC, Nant Capital, LLC, California Capital Equity, LLC, NantBio, Inc., NantCancerStemCell, LLC, and the Chan Soon-Shiong Family Foundation.
- The Nominating Agreement and Registration Rights Agreement are with Cambridge Equities, LP, an entity beneficially owned by Dr. Soon-Shiong.
Stakeholder Impact
- Shareholders: The high concentration of ownership by Dr. Patrick Soon-Shiong and his affiliated entities (68.9%) indicates strong control over the company's strategic direction and voting matters, potentially limiting the influence of minority shareholders.
- Creditors: The existence of a promissory note convertible into a significant number of shares (93,053,252 shares for Nant Capital) could impact the company's capital structure and future dilution.
Next Steps
- Potential conversion of a promissory note by Nant Capital, LLC to acquire 93,053,252 shares within 60 days of October 30, 2025.
- Potential exercise of stock options by Dr. Patrick Soon-Shiong to acquire 1,123,929 shares within 60 days of October 30, 2025.
Key Dates
| Date | Description |
|---|---|
| 12/23/2014 | Date of Registration Rights Agreement between the Issuer and Cambridge Equities, LP. |
| 06/18/2015 | Date of Nominating Agreement between the Issuer and Cambridge Equities, LP. |
| 09/21/2023 | Date of Joint Filing Agreement among reporting persons (incorporated by reference). |
| 10/30/2025 | Date as of which the number of issued and outstanding shares and beneficial ownership percentages were calculated. |
| 11/10/2025 | Date of event which requires filing of this statement and filing date of the amendment. |
Recommendation
holdThis filing is a routine amendment to disclose beneficial ownership. While it confirms a high level of insider ownership, it does not provide new operational or financial data to warrant a change in investment thesis. Investors should 'hold' and await further operational updates.
Keywords
ImmunityBio, IBRX, Schedule 13D, beneficial ownership, Patrick Soon-Shiong, NantWorks, Nant Capital, common stock, insider ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.